dipyridamole has been researched along with Brain Emboli in 9 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking." | 1.32 | Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weber, R | 1 |
| Weimar, C | 1 |
| Wanke, I | 1 |
| Möller-Hartmann, C | 1 |
| Gizewski, ER | 1 |
| Blatchford, J | 1 |
| Hermansson, K | 1 |
| Demchuk, AM | 1 |
| Forsting, M | 1 |
| Sacco, RL | 1 |
| Saver, JL | 1 |
| Warach, S | 1 |
| Diener, HC | 1 |
| Diehl, A | 1 |
| CASELLAS BERNAT, A | 1 |
| TRILLA SANCHEZ, E | 1 |
| DE-VOS BERRUETA, M | 1 |
| GAUSI GENE, C | 1 |
| Ruel, M | 1 |
| Masters, RG | 1 |
| Rubens, FD | 1 |
| Bédard, PJ | 1 |
| Pipe, AL | 1 |
| Goldstein, WG | 1 |
| Hendry, PJ | 1 |
| Mesana, TG | 1 |
| Fieschi, C | 1 |
| Volante, F | 1 |
| Derendorf, H | 1 |
| Aldandashi, S | 1 |
| Noor, R | 1 |
| Wang, CX | 1 |
| Uddin, G | 1 |
| Shuaib, A | 1 |
| de Borst, GJ | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| Moll, FL | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Macdonald, S | 1 |
| Lalouschek, W | 1 |
| Lang, W | 1 |
| Müllner, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744] | 3,400 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
2 trials available for dipyridamole and Brain Emboli
| Article | Year |
|---|---|
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
7 other studies available for dipyridamole and Brain Emboli
| Article | Year |
|---|---|
[Clinico-experipyrimido (5,4-d) pyrimidine].
Topics: Angina Pectoris; Dipyridamole; Heart Diseases; Humans; Intracranial Embolism; Intracranial Embolism | 1963 |
Late incidence and determinants of stroke after aortic and mitral valve replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral | 2004 |
Platelet emboli and ischemia in rabbit's brain caused by ADP or arachidonic acid and the protective effect of ASA and dipyridamole.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Aspirin; Dipyridamole; Intracranial Embolism; Isch | 1977 |
Clinical trials and dipyridamole formulation selection.
Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug | 2007 |
Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats.
Topics: Animals; Aspirin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Dipyridamole; Drug Therap | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |